- Home
- INTA vs SRPT Comparison
INTA vs SRPT Comparison
Compare INTA & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INTA | SRPT |
|---|---|---|
| Founded | 2000 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | INTA | SRPT |
|---|---|---|
| Price | $22.73 | $17.64 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 29 |
| Target Price | ★ $41.43 | $25.85 |
| AVG Volume (30 Days) | 1.0M | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.89 | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | $504,120,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $15.91 | N/A |
| Revenue Next Year | $13.78 | N/A |
| P/E Ratio | ★ N/A | $5.99 |
| Revenue Growth | ★ 17.09 | 15.58 |
| 52 Week Low | $19.01 | $10.42 |
| 52 Week High | $58.79 | $43.92 |
Technical Indicators
Market Signals| Indicator | INTA | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 54.71 | 42.49 |
| Support Level | $20.29 | $17.11 |
| Resistance Level | $25.62 | $18.10 |
| Average True Range (ATR) | 1.53 | 0.77 |
| MACD | 0.05 | -0.09 |
| Stochastic Oscillator | 60.51 | 28.85 |
Price Performance
Historical ComparisonAbout INTA Intapp Inc.
Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital,g, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.